Publications

1. Patel BK, Carnahan MB, Northfelt D, Anderson K, Mazza GL, Pizzitola VJ, Giurescu ME, Lorans R, Eversman WG, Sharpe RE Jr, Harper LK, Apsey H, Cronin P, Kling J, Ernst B, Palmieri J, Fraker J, Mina L, Batalini F, Pockaj B. Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round. J Clin Oncol. 2024 Nov 10; 42 (32):3826-3836 Epub 2024 July 26
   View PubMed
2. Patel BK, Gurudu R, Mazza G, Sharpe RE Jr, Mina L, Fraker J, Kling JM, Anderson K, Hughes D, Pockaj B. Patient-Reported Testing Burden of Screening Contrast-Enhanced Mammography. J Am Coll Radiol. 2024 May; 21 (5):789-794 Epub 2023 Nov 11
   View PubMed
3. Wilson E, Cava JK, Chowell D, Raja R, Mangalaparthi KK, Pandey A, Curtis M, Anderson KS, Singharoy A. The electrostatic landscape of MHC-peptide binding revealed using inception networks. Cell Syst. 2024 Apr 17; 15 (4):362-373.e7 Epub 2024 Mar 29
   View PubMed
4. Seyedi S, Teo R, Foster L, Saha D, Mina L, Northfelt D, Anderson KS, Shibata D, Gatenby R, Cisneros LH, Troan B, Anderson ARA, Maley CC. Testing Adaptive Therapy Protocols Using Gemcitabine and Capecitabine in a Preclinical Model of Endocrine-Resistant Breast Cancer. Cancers (Basel). 2024 Jan 6; 16 (2) Epub 2024 Jan 06
   View PubMed
5. Roesler AS, Malasi S, Koslosky L, Hartmayer P, Naab TJ, Carter JM, Zahrieh D, Hillman D, Leon-Ferre RA, Couch FJ, Goetz MP, Anderson KS, Pockaj BA, Barrett MT. PDJ amplicon in triple negative breast cancer. Sci Rep. 2023 Jan 12; 13 (1):618
   View PubMed
6. Anderson KS, Erick TK, Chen M, Daley H, Campbell M, Colson Y, Mihm M, Zakka LR, Hopper M, Barry W, Winer EP, Dranoff G, Overmoyer B. The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers. Breast Cancer Res Treat. 2022 Jul; 194 (1):65-78 Epub 2022 Apr 28
   View PubMed
7. Patel BK, Pepin K, Brandt KR, Mazza GL, Pockaj BA, Chen J, Zhou Y, Northfelt DW, Anderson K, Kling JM, Vachon CM, Swanson KR, Nikkhah M, Ehman R. Association of breast cancer risk, density, and stiffness: global tissue stiffness on breast MR elastography (MRE). Breast Cancer Res Treat. 2022 Jul; 194 (1):79-89 Epub 2022 Apr 30
   View PubMed
8. Schuman A, Anderson KS, Day AT, Ferrell J, Sturgis EM, Dahlstrom KR. Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic. Expert Rev Anticancer Ther. 2022 Jul; 22 (7):751-761 Epub 2022 June 17
   View PubMed
9. Mishra R, Alam R, McAuley D, Bharaj T, Chung D, Kinahan DJ, Nwankire C, Anderson KS, Ducree J. Solvent selective membrane routing and microfluidic architecture towards centrifugal automation of customisable bead based immunoassays. Sensors and Actuators B: Chemical. 2022 Apr; 356.
   
10. Roesler AS, Anderson KS. Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines. Methods Mol Biol. 2022; 2410:649-670
    View PubMed
11. Fortin Ensign SP, Yancey E, Anderson KS, Mrugala MM. Safety and Feasibility of Intrathecal Pembrolizumab Infusion in Refractory Triple Negative Breast Cancer with Leptomeningeal Disease: A Case Report. Current Problems in Cancer: Case Reports. 2021; 4:100103. Epub 2021 Jul 21.
    
12. Dahlstrom KR, Anderson KS, Guo M, Kwon MC, Messick CA, Pettaway CA, Asomaning N, Hopper M, Price A, Xu L, Day AT, Gillenwater AM, Sturgis EM. Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial. Oral Oncol. 2021 Sep; 120:105397 Epub 2021 June 26
    View PubMed
13. Phung TN, Webster TH, Lenkiewicz E, Malasi S, Andreozzi M, McCullough AE, Anderson KS, Pockaj BA, Wilson MA, Barrett MT. Unique evolutionary trajectories of breast cancers with distinct genomic and spatial heterogeneity. Sci Rep. 2021 May 19; 11 (1):10571
    View PubMed
14. Romero-Brufau S, Chopra A, Ryu AJ, Gel E, Raskar R, Kremers W, Anderson KS, Subramanian J, Krishnamurthy B, Singh A, Pasupathy K, Dong Y, O'Horo JC, Wilson WR, Mitchell O, Kingsley TC. Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study. BMJ. 2021 May 12; 373:n1087.
    View PubMed
15. Wilson EA, Hirneise G, Singharoy A, Anderson KS. Total predicted MHC-I epitope load is inversely associated with population mortality from SARS-CoV-2. Cell Rep Med. 2021 Mar 16; 2 (3):100221 Epub 2021 Feb 25
    View PubMed
16. Phung TN, Lenkiewicz E, Malasi S, Sharma A, Anderson KS, Wilson MA, Pockaj BA, Barrett MT. Unique genomic and neoepitope landscapes across tumors: a study across time, tissues, and space within a single lynch syndrome patient. Sci Rep. 2020 Jul 22; 10 (1):12190 Epub 2020 July 22
    View PubMed
17. Hilal T, Mi L, Ertz-Archambault NM, Almquist DR, Anderson KS, Gray RJ, Pockaj BA, Northfelt DW. Change in 21-gene Recurrence Score result after exposure to neo-adjuvant endocrine therapy in patients with operable breast cancer. Breast J. 2020 Jul; 26 (7):1449-1451 Epub 2019 Dec 26
    View PubMed
18. Ertz-Archambault NM, Rogoff LB, Kosiorek HE, Ernst BJ, Anderson KS, Pockaj BA, Gray RJ, Northfelt DW. Depomedroxyprogesterone acetate therapy for hot flashes in survivors of breast cancer: no unfavorable impact on recurrence and survival. Support Care Cancer. 2020 May; 28 (5):2139-2143 Epub 2019 Aug 11
    View PubMed
19. Calderon E, Webb C, Kosiorek HE, Richard J Gray MD, Cronin P, Anderson K, Northfelt D, McCullough A, Ocal IT, Pockaj B. Are we choosing wisely in elderly females with breast cancer? Am J Surg. 2019 Dec; 218 (6):1229-1233 Epub 2019 Aug 10
    View PubMed
20. McDonald BR, Contente-Cuomo T, Sammut SJ, Odenheimer-Bergman A, Ernst B, Perdigones N, Chin SF, Farooq M, Mejia R, Cronin PA, Anderson KS, Kosiorek HE, Northfelt DW, McCullough AE, Patel BK, Weitzel JN, Slavin TP, Caldas C, Pockaj BA, Murtaza M. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci Transl Med. 2019 Aug 7; 11 (504)
    View PubMed
21. Ferdosi SR, Ewaisha R, Moghadam F, Krishna S, Park JG, Ebrahimkhani MR, Kiani S, Anderson KS. Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes. Nat Commun. 2019 Apr 23; 10 (1):1842
    View PubMed
22. Henderson MC, Silver M, Tran Q, Letsios EE, Mulpuri R, Reese DE, Lourenco AP, LaBaer J, Anderson KS, Alpers J, Costantini C, Rohatgi N, Ali H, Baker K, Northfelt DW, Ghosh K, Grobmyer SR, Polen W, Wolf JK. A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment. Clin Cancer Res. 2019 Jan 1; 25 (1):142-149 Epub 2018 Sept 05
    View PubMed
23. Wilson EA, Anderson KS. Lost in the crowd: identifying targetable MHC class I neoepitopes for cancer immunotherapy. Expert Rev Proteomics. 2018 Dec; 15 (12):1065-1077 Epub 2018 Nov 14
    View PubMed
24. Chen M, Pockaj B, Andreozzi M, Barrett MT, Krishna S, Eaton S, Niu R, Anderson KS. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer. Clin Breast Cancer. 2018 Oct; 18 (5):e1205-e1215 Epub 2018 May 26
    View PubMed
25. Barrett MT, Lenkiewicz E, Malasi S, Basu A, Yearley JH, Annamalai L, McCullough AE, Kosiorek HE, Narang P, Wilson Sayres MA, Chen M, Anderson KS, Pockaj BA. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers. Breast Cancer Res. 2018 Jul 11; 20 (1):71 Epub 2018 July 11
    View PubMed
26. Obahiagbon U, Smith JT, Zhu M, Katchman BA, Arafa H, Anderson KS, Blain Christian JM. A compact, low-cost, quantitative and multiplexed fluorescence detection platform for point-of-care applications (in press) Biosensors and Bioelectronics. 2018 Apr.
    
27. Kaaks R, Fortner RT, Husing A, Barrdahl M, Hopper M, Johnson T, Tjonneland A, Hansen L, Overvad K, Fournier A, Boutron-Ruault MC, Kvaskoff M, Dossus L, Johansson M, Boeing H, Trichopoulou A, Benetou V, La Vecchia C, Sieri S, Mattiello A, Palli D, Tumino R, Matullo G, Onland-Moret NC, Gram IT, Weiderpass E, Sanchez MJ, Navarro Sanchez C, Duell EJ, Ardanaz E, Larranaga N, Lundin E, Idahl A, Jirstrom K, Nodin B, Travis RC, Riboli E, Merritt M, Aune D, Terry K, Cramer DW, Anderson KS. Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation. Int J Cancer. 2018 Feb 22 [Epub ahead of print]
    View PubMed
28. Chowell D, Napier J, Gupta R, Anderson KS, Maley CC, Sayres MAW. Modeling the Subclonal Evolution of Cancer Cell Populations. Cancer Res. 2018 Feb 1; 78 (3):830-839 Epub 2017 Nov 29
    View PubMed
29. Ferdosi S, Rehder DS, Maranian P, Castle EP, Ho TH, Pass HI, Cramer DW, Anderson KS, Fu L, Cole DEC, Le T, Wu X, Borges CR. Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, beta1-4 Branching, beta1-6 Branching, and alpha2-6 Sialylation in Cancer. J Proteome Res. 2018 Jan 5; 17 (1):543-558 Epub 2017 Nov 21
    View PubMed
30. Dahlstrom KR, Anderson KS, Field MS, Chowell D, Ning J, Li N, Wei Q, Li G, Sturgis EM. Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus-related oropharyngeal cancer. Cancer. 2017 Dec 15; 123 (24):4886-4894 Epub 2017 Sept 12
    View PubMed
31. Chang JM, Kosiorek HE, Wasif N, Gray RJ, Stucky CH, Northfelt DW, Anderson KS, McCullough AE, Tolgay Ocal I, Pockaj BA. Discussion of: "The success of sentinel lymph node biopsy after neoadjuvant therapy: A single institution review". Am J Surg 2017 Dec; 214 (6):1102-1103 Epub 2017 Sept 30
    View PubMed
32. Chang JM, Kosiorek HE, Wasif N, Gray RJ, Stucky CH, Northfelt DW, Anderson KS, McCullough AE, Ocal IT, Pockaj BA. The success of sentinel lymph node biopsy after neoadjuvant therapy: A single institution review. Am J Surg. 2017 Dec; 214 (6):1096-1101 Epub 2017 Sept 18
    View PubMed
33. Chen M, Andreozzi M, Pockaj B, Barrett MT, Ocal IT, McCullough AE, Linnaus ME, Chang JM, Yearley JH, Annamalai L, Anderson KS. Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification. Mod Pathol. 2017 Nov; 30 (11):1516-1526 Epub 2017 July 28
    View PubMed
34. Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M, Yuan Y, Pienta KJ, Anderson KS, Gatenby R, Swanton C, Posada D, Wu CI, Schiffman JD, Hwang ES, Polyak K, Anderson ARA, Brown JS, Greaves M, Shibata D. Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer. 2017 Oct; 17 (10):605-619 Epub 2017 Sept 15
    View PubMed
35. Anderson KS, Wallstrom G, Langseth H, Posner M, Cheng JN, Alam R, Chowell D, Furre IE, Mork J. Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer. Oral Oncol. 2017 Oct; 73:132-137 Epub 2017 Sept 01
    View PubMed
36. Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, Hoog J, Naughton M, Ademuyiwa F, Suresh R, Anderson KS, Margenthaler J, Aft R, Hobday T, Moynihan T, Gillanders W, Cyr A, Eberlein TJ, Hieken T, Krontiras H, Guo Z, Lee MV, Spies NC, Skidmore ZL, Griffith OL, Griffith M, Thomas S, Bumb C, Vij K, Bartlett CH, Koehler M, Al-Kateb H, Sanati S, Ellis MJ. NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4055-4065. Epub 2017 Mar 07.
    View PubMed
37. Katchman BA, Chowell D, Wallstrom G, Vitonis AF, LaBaer J, Cramer DW, Anderson KS. Autoantibody biomarkers for the detection of serous ovarian cancer. Gynecol Oncol. 2017 Jul; 146 (1):129-136 Epub 2017 Apr 18
    View PubMed
38. Inan H, Wang S, Inci F, Baday M, Zangar R, Kesiraju S, Anderson KS, Cunningham BT, Demirci U. Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies. Sci Rep. 2017 Jun 12; 7 (1):3322 Epub 2017 June 12
    View PubMed
39. Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. Ann Oncol. 2017 May 1; 28 (5):996-1004
    View PubMed
40. Hanna GJ, Sridharan V, Margalit DN, La Follette SK, Chau NG, Rabinowits G, Lorch JH, Haddad RI, Tishler RB, Anderson KS, Schoenfeld JD. Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomark. 2017; 19 (2):129-136
    View PubMed
41. Ewaisha R, Panicker G, Maranian P, Unger ER, Anderson KS. Serum Immune Profiling for Early Detection of Cervical Disease. Theranostics. 2017; 7 (16):3814-3823 Epub 2017 Aug 23
    View PubMed
42. Dahlstrom KR, Anderson KS, Sturgis EM. Human Papillomavirus-Associated Oropharyngeal Cancer: Not Just White Men Anymore. JAMA Oncol. 2016 Dec 8 Epub 2016 Dec 08
    View PubMed
43. Katchman BA, Smith JT, Obahiagbon U, Kesiraju S, Lee YK, O'Brien B, Kaftanoglu K, Blain Christen J, Anderson KS. Application of flat panel OLED display technology for the point-of-care detection of circulating cancer biomarkers. Sci Rep. 2016 Jul 4; 6:29057 Epub 2016 July 04
    View PubMed
44. Katchman BA, Barderas R, Alam R, Chowell D, Field MS, Esserman LJ, Wallstrom G, LaBaer J, Cramer DW, Hollingsworth MA, Anderson KS. Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers. Proteomics Clin Appl. 2016 Jul; 10 (7):720-31 Epub 2016 May 17
    View PubMed
45. Ewaisha R, Meshay I, Resnik J, Katchman BA, Anderson KS. Programmable protein arrays for immunoprofiling HPV-associated cancers. Proteomics. 2016 Apr; 16 (8):1215-24 Epub 2016 Apr 04
    View PubMed
46. Smith JT, Katchman BA, Kullman DE, Obahiagbon U, Lee YK, O'Brien BP, Raupp GB, Anderson KS, Blain Christen J. Application of flexible OLED display technology to pointof-care medical diagnostic testing Journal of Display Technology. 2016 Mar; 12(3):273-80.
    
47. Ewaisha R, Gawryletz CD, Anderson KS. Crucial considerations for pipelines to validate circulating biomarkers for breast cancer. Expert Rev Proteomics. 2016; 13 (2):201-11 Epub 2016 Jan 04
    View PubMed
48. Linnaus ME, Dueck AC, Kosiorek HE, Gray RJ, Wasif N, Northfelt DW, Anderson KS, McCullough AE, Wong WW, Halyard MY, Patel SH, Pockaj BA. Regional recurrence in the era of sentinel lymph node biopsy. Am J Surg. 2015 Dec; 210 (6):1155-60; discussion 1160-1 Epub 2015 Sept 28
    View PubMed
49. Chang JM, McCullough AE, Dueck AC, Kosiorek HE, Ocal IT, Lidner TK, Gray RJ, Wasif N, Northfelt DW, Anderson KS, Pockaj BA. Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S509-15.
    View PubMed
50. Barrett MT, Anderson KS, Lenkiewicz E, Andreozzi M, Cunliffe HE, Klassen CL, Dueck AC, McCullough AE, Reddy SK, Ramanathan RK, Northfelt DW, Pockaj BA. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget. 2015 Sep 22; 6 (28):26483-93
    View PubMed
51. Wang J, Figueroa JD, Wallstrom G, Barker K, Park JG, Demirkan G, Lissowska J, Anderson KS, Qiu J, LaBaer J. Plasma Autoantibodies Associated with Basal-like Breast Cancers. Cancer Epidemiol Biomarkers Prev. 2015 Sep; 24 (9):1332-40 Epub 2015 June 12
    View PubMed
52. Anderson KS, Gerber JE, D'Souza G, Pai SI, Cheng JN, Alam R, Kesiraju S, Chowell D, Gross ND, Haddad R, Gillison ML, Posner M. Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. Oral Oncol. 2015 Aug; 51 (8):751-8 Epub 2015 June 18
    View PubMed
53. Anderson KS, Dahlstrom KR, Cheng JN, Alam R, Li G, Wei Q, Gross ND, Chowell D, Posner M, Sturgis EM. HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status. Oral Oncol. 2015 Jul; 51 (7):662-7 Epub 2015 May 06
    View PubMed
54. Dahlstrom KR, Anderson KS, Cheng JN, Chowell D, Li G, Posner M, Sturgis EM. HPV Serum Antibodies as Predictors of Survival and Disease Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the Oropharynx. Clin Cancer Res. 2015 Jun 15; 21 (12):2861-9
    View PubMed
55. Chowell D, Krishna S, Becker PD, Cocita C, Shu J, Tan X, Greenberg PD, Klavinskis LS, Blattman JN, Anderson KS. TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes. Proc Natl Acad Sci U S A. 2015 Apr 7; 112 (14):E1754-62 Epub 2015 Mar 23
    View PubMed
56. Ernst B, Anderson KS. Immunotherapy for the treatment of breast cancer. Curr Oncol Rep. 2015 Feb; 17 (2):5
    View PubMed
57. Marks JR, Anderson KS, Engstrom P, Godwin AK, Esserman LJ, Longton G, Iversen ES, Mathew A, Patriotis C, Pepe MS. Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease. Cancer Epidemiol Biomarkers Prev. 2015 Feb; 24 (2):435-41 Epub 2014 Dec 03
    View PubMed
58. Anderson KS, Cramer DW, Sibani S, Wallstrom G, Wong J, Park J, Qiu J, Vitonis A, LaBaer J. Autoantibody signature for the serologic detection of ovarian cancer. J Proteome Res. 2015 Jan 2; 14 (1):578-86 Epub 2014 Nov 17
    View PubMed
59. D'Souza G, Gross ND, Pai SI, Haddad R, Anderson KS, Rajan S, Gerber J, Gillison ML, Posner MR. Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol. 2014 Aug 10; 32 (23):2408-15 Epub 2014 Apr 28
    View PubMed
60. Zeng W, Su M, Anderson KS, Sasada T. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens. Immunobiology. 2014 Aug; 219 (8):583-92 Epub 2014 Mar 20
    View PubMed
61. Siufi Neto J, Kho RM, Siufi DF, Baracat EC, Anderson KS, Abrao MS. Cellular, histologic, and molecular changes associated with endometriosis and ovarian cancer. J Minim Invasive Gynecol. 2014 Jan-Feb; 21(1):55-63. Epub 2013 Aug 17.
    View PubMed
62. Wang J, Barker K, Steel J, Park J, Saul J, Festa F, Wallstrom G, Yu X, Bian X, Anderson KS, Figueroa JD, LaBaer J, Qiu J. A versatile protein microarray platform enabling antibody profiling against denatured proteins. Proteomics Clin Appl. 2013 Jun; 7 (5-6):378-83 Epub 2013 May 17
    View PubMed
63. Wallstrom G, Anderson KS, LaBaer J. Biomarker discovery for heterogeneous diseases. Cancer Epidemiol Biomarkers Prev. 2013 May; 22(5):747-55. Epub 2013 Mar 05.
    View PubMed
64. Jaras K, Anderson KS. Autoantibodies in cancer: Prognostic Biomarkers and immune activation. Solicited review Expert Rev Proteomics. 2011 Oct; 8(5):577-89. Review.
    
65. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, Wu Z, Gonen M, Mulvey LA, Bessarabova MO, Huh SJ, Silver SJ, Kim SY, Park SY, Lee HE, Anderson KS, Richardson AL, Nikolskaya T, Nikolsky Y, Liu XS, Root DE, Hahn WC, Frank DA, Polyak K. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011 Jul; 121(7):2723-35.
    View PubMed
66. Anderson KS, Wong J, D'Souza G, Riemer AB, Lorch J, Haddad R, Pai SI, Longtine J, McClean M, LaBaer J, Kelsey KT, Posner M. Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. Br J Cancer. 2011 Jun 7; 104(12):1896-905.
    View PubMed
67. Anderson KS, Zeng W, Sasada T, Choi J, Riemer AB, Su M, Drakoulakos D, Kang YJ, Brusic V, Wu C, Reinherz EL. Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells. Cancer Immunol Immunother. 2011 Jun; 60(6):857-67. Epub 2011 Mar 13.
    View PubMed
68. Chen J, Yao Y, Gong C, Yu F, Su S, Chen J, Liu B, Deng H, Wang F, Lin L, Yao H, Su F, Anderson KS, Liu Q, Ewen ME, Yao X, Song E. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell. 2011 Apr 12; 19 (4):541-55
    View PubMed
69. Yang C, Hayashida T, Forster N, Li C, Shen D, Maheswaran S, Chen L, Anderson KS, Ellisen LW, Sgroi D, Schmidt EV. The integrin alpha(v)beta(3-5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers. Cancer Res. 2011 Feb 1; 71(3):937-45. Epub 2010 Dec 2.
    View PubMed
70. Anderson KS, Sibani S, Wallstrom G, Qiu J, Mendoza EA, Raphael J, Hainsworth E, Montor WR, Wong J, Park JG, Lokko N, Logvinenko T, Ramachandran N, Godwin AK, Marks J, Engstrom P, Labaer J. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res. 2011 Jan 7; 10(1):85-96. Epub 2010 Nov 23.
    View PubMed
71. Anderson KS. Multiplexed detection of antibodies using programmable bead arrays. Methods Mol Biol. 2011; 723:227-38.
    View PubMed
72. Marotta L, Almendro V, Shipitsin M, Marusyk A, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, Wu Z, Gönen M, Mulvey LA, Bessarabova MO, Huh SJ, Silver SJ, Kim SY, Park SY, Lee HE, Anderson KS, Richardson AL, Nikolskaya T, Nikolsky Y, Liu XS, Root DE, Hahn WC, Frank DA, Polyak K. Specific activation and requirement of Stat3 in CD44+CD24- breast cancer cells. Journal of Clinical Investigation. 2011; 121:2723-35.
    
73. Anderson KS, Petersson S, Wong J, Shubbar E, Lokko NN, Carlstrom M, Enerback C. Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris. Br J Dermatol. 2010 Nov; 163(5):1085-9.
    View PubMed
74. Reimer A, Keskin D, Zhang G, Handley M, Anderson KS, Brusic V, Reinhold B, Reinherz E. A conserved E7-derived CTL epitope expressed on human papillomavirus-16 transformed HLA-A2+ human epithelial cancers. J Biol Chem. 2010 Sep 17; 285(38):29608-22.
    
75. Anderson KS, Wong J, Vitonis A, Crum CP, Sluss PM, LaBaer J, Cramer D. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epi Biomark and Prev. 2010 Mar; 19(3):859-68.
    
76. Tabernero MD, Lv LL, Anderson KS. Autoantibody profiles as biomarkers of breast cancer. Cancer Biomark. 2010; 6(5-6):247-56.
    View PubMed
77. Wong J, Sibani S, Lokko NL, LaBaer J, Anderson KS. Rapid detection of antibodies in sera using multiplexed self-assembling bead arrays. J Immunol Methods. 2009 Oct 31; 350(1-2):171-82.
    
78. Mirshahidi S, Kramer VG, Whitney JB, Essono S, Lee S, Anderson KS, Dranoff G, Ruprecht RM. Reduced tumor growth and prolong survival after immunization of mice with overlapping synthetic peptides covering tumor protein D52. Vaccine. 2009 Mar 13; 27(12):1825-33.
    
79. Anderson KS, Wong J, Polyak K, Aronzon D, Enerback C. Detection of psoriasin/S100A7 in the sera of psoriatic patients. Br J Dermatol. 2009 Feb; 160(2):325-32.
    
80. Ramachandran N, Anderson KS, Raphael JV, Hainsworth E, Sibani S, Montor WR, Pacek M, Wong J, Eljanne M, Sanda MG, Hu Y, Logvinenko T, Labaer J. Tracking humoral responses using self assembling protein microarrays. Proteomics Clin Appl. 2008 Oct; 2(10-11):1518-27. Epub 2008 Sep 10.
    View PubMed
81. Anderson KS, Ramachandran N, Wong J, Raphael JV, Hainsworth E, Demirkan G, Cramer D, Aronzon D, Hodi FS, Harris L, Logvinenko T, Labaer J. Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res. 2008 Apr 4; 7(4):1490-9.
    
82. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007 Mar; 11(3):259-73.
    
83. Maecker B, Von Bergwelt-Baildon MS, Anderson KS, Vonderheide RH, Anderson KC, Nadler LM, Schultze JL. Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clin Exp Immunol. 2005 Sep; 141(3):558-62.
    
84. Weihrauch MR, Ansen S, Jurkeiwicz E, Geisen C, Xia Z, Anderson KS, Gracien E, Schmidt M, Wittig B, Diehl V, Wolf J, Bohlen H, Nadler LM. Phase I/II combined immuno-/chemotherapy with CEA derived HLA-A2 restricted CAP-1 peptide and irinotecan 5-fluorouracil and leucovorin in patients with primary metastatic colorectal cancer. Clin Cancer Res. 2005 Aug 15; 11(16):5993-6001.
    
85. Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res. 2005 Jul-Aug; 4(4):1123-33. Review.
    
86. Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen D-Y, Stephans KF, Masutomi K, Loda M, Xia Z, Anderson KS, Hahn WC, Nadler LM. Vaccination of cancer patients against telomerase induces functional anti-tumor CD8+ T lymphocytes. Clin Cancer Res. 2004 Feb 1; 10:828-39.
    
87. Maecker B, Sherr DH, Vonderheide RH, Von Bergwelt-Baildon MS, Hirano N, Anderson KS, Xia Z, Butler MO, Wucherpfennig KW, O'Hara C, Cole G, Kwak SS, Ramstedt U, Tomlinson AJ, Chicz RM, Nadler LM, Schultze JL. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood. 2003 Nov 1; 102(9):3287-94.
    
88. Maecker B, Anderson KS, von Bergwelt-Baildon MS, Weller E, Vonderheide RH, Richardson PG, Schlossman RL, Menezes IA, Xia Z, Munshi NC, Anderson KC, Nadler LM, Schultze JL. Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. British J Haematology. 2003 Jun; 121(6):842-8.
    
89. Von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Anderson KS, Hirano N, Wucherpfennig KW, Nadler LM, Schultze JL. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced using CD40-activated B cells as antigen presenting cells: Potential for clinical application. Blood. 2002 May 1; 99(9):3319-25.
    
90. Vonderheide RH, Schultze JL, Anderson KS, Maecker B, Butler MO, Xia Z, Kuroda MJ, Bergwelt-Baildon MS, Bedor MM, Hoar KM, Schnipper DR, Brooks MW, Letvin NL, Stephans KF, Wucherpfennig KW, Hahn WC, Nadler LM. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res. 2001 Dec 1; 62(23):8366-70.
    
91. Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM. Characterization of HLA-A3-restricted T cells reactive against the universal tumor antigen telomerase for widely applicable anti-cancer immunotherapy. Clin Cancer Res. 2001 Nov; 7(11):3343-8.
    
92. Maecker B, von Bergwelt-Baildon, Anderson KS, Vonderheide RH, Schultze JL. Linking genomics to immunotherapy by reverse immunology--'immunomics' in the new millennium. Curr Mol Med. 2001 Nov; 1(5):609-19. Review.
    
93. Schultze JL, Maecker B, von Bergwelt-Baildon MS, Anderson KS, Vonderheide RH. Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens. Vox Sang. 2001 Feb; 80(2):81-9.
    View PubMed
94. Anderson KS, Cresswell P. A role for calnexin (IP90) in the assembly of class II MHC molecules. EMBO. 1994; 13:675-82.
    
95. Anderson KS, Alexander JA, Wei ML, Cresswell P. Intracellular transport of class I MHC molecules in antigen processing mutant cell lines. J Immunol. 1993; 151:3407-19.
    
96. Androlewicz M, Anderson KS, Cresswell P. Transporters of antigenic peptides (TAP proteins) translocate a MHC class I binding peptide into the ER in a ATP-dependent manner. Proc Natl Acad Sci USA. 1993; 90:9130-4.
    
97. Click E-M, Anderson KS, Androlewicz MJ, Wei ML, Cresswell P. Transport and expression of class I MHC glycoproteins in an antigen processing-mutant cell line. CSH Symp Quant Biol. 1992; LVII:571-77.
    
98. Anderson K, Cresswell P, Gammon M, Hermes J, Williamson A, Zweerink H. Endogenously synthesized peptide with an ER signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. J Exp Med. 1991; 174:489-92.
    
99. Cerundulo V, Alexander J, Anderson K, Lamb C, Cresswell P, McMichael A, Gotch F, Townsend A. Presentation of viral antigen controlled by a gene in the MHC. Nature. 1990; 345:449-52.
    
100. Pearson, WR, Reinhart, J, Sisk, SC, Anderson KS, Adler PN. Tissue specific induction of murine glutathione transferase mRNAs by butylated hydroxyanisole. J Biol Chem. 1988; 263:13324-32.